Merck Gets EU Nod for U.S. Biotech Millipore Buy

German drugmaker Merck secured EU regulatory approval on Wednesday for its takeover of U.S. biotech tool maker Millipore, marking a diversification away from the pharmaceuticals business.

Merck, maker of the multiple sclerosis drug Rebif and owner of the rights to cancer drug Erbitux in Europe, unveiled the $6 billion deal in March. Analysts had said the transaction made sense as Merck's liquid crystals unit, its main cash cow, faces increasing competition from Asian rivals.

"Although the parties are both active in the life science business, they focus on different markets," the European Commission said in a statement.

The two groups' activities overlap modestly in the market for air monitoring systems, but their combined market shares remained relatively low, the Commission said.

Given the presence of strong competitors, the Commission concluded that the transaction did not raise competition concerns. Millipore makes filters and purifiers for laboratory water and other materials used in making biotechnology drugs.

Read CHEManager Europe's interview with Merck Chairman Dr. Karl-Ludwig Kley here.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read